Status:
RECRUITING
OnaBotulinumtoxin-A in Chronic Migraine Patients with Short or Long Disease History (the BACH Study)
Lead Sponsor:
Fondazione Policlinico Universitario Campus Bio-Medico
Conditions:
Migraine
Eligibility:
All Genders
18-70 years
Brief Summary
The goal of this observational prospective multicentric study, 12 months duration is to investigate whether the history of Chronic Migraine and, more precisely, its duration for over or less than 10 y...
Detailed Description
Onabotulinumtoxin-A (OBT-A) is a worldwide approved preventive treatment for patients suffering from Chronic Migraine (CM, 1.3, ICHD III 2018). Its effectiveness in reducing headache frequency and dis...
Eligibility Criteria
Inclusion
- Age between 18 and 70 years-old
- Chronic Migraine defined according to 1.3 ICHD-3
- Informed consent
Exclusion
- secondary headache
- Onabotulinumtoxin-A in the previous 3 months
- pregnancy or breastfeeding
- detoxification protocol for Medication Overuse Headache in the last 6 months
Key Trial Info
Start Date :
January 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
115 Patients enrolled
Trial Details
Trial ID
NCT06537700
Start Date
January 1 2024
End Date
December 31 2025
Last Update
September 19 2024
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Università Politecnica delle Marche
Ancona, Italy
2
Università Studi dell'Aquila
L’Aquila, Italy
3
IRCCS Istituto Auxologico Italiano
Milan, Italy
4
Istituto Neurologico Besta
Milan, Italy